Greenlane, PA, United States of America

Charles A Sutherland


Average Co-Inventor Count = 4.6

ph-index = 3

Forward Citations = 27(Granted Patents)


Company Filing History:


Years Active: 1993-1995

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Charles A. Sutherland

Introduction

Charles A. Sutherland, based in Greenlane, Pennsylvania, is a distinguished inventor recognized for his notable contributions in the field of pharmaceuticals. With three patents to his name, Sutherland has made significant strides in the development of compounds that target leukotriene activity, offering therapeutic implications for various disorders.

Latest Patents

Sutherland's latest patents showcase his expertise in medicinal chemistry. His works include:

1. Substituted naphthylene compounds exhibiting selective leukotriene activity.

2. Substituted monocyclic aryl compounds exhibiting selective leukotriene activity.

3. Monocyclic aryl compounds that possess selective LTB4 antagonist properties, which include amido substituents, terminal carboxylic acid derivatives, and lipophilic groups, along with therapeutic compositions and methods for treating disorders caused by LTB4 activity.

Career Highlights

Currently associated with Rhone-Poulenc Rorer Pharmaceuticals Inc., Sutherland has leveraged his innovative spirit to advance the pharmaceutical industry. His patents reflect a commitment to exploring new therapeutic avenues aimed at alleviating conditions linked to leukotriene activity, significantly impacting patient care.

Collaborations

Throughout his career, Sutherland has collaborated with talented professionals, including Fu-Chih Huang and Wan K. Chan. These partnerships have fostered an environment of innovation, culminating in the successful development and patenting of novel compounds.

Conclusion

In summary, Charles A. Sutherland stands out as a prominent figure in the realm of pharmaceutical innovation. His extensive work on leukotriene-targeting compounds underlines the importance of collaboration and dedication to advancing medical treatment options. With a strong patent portfolio, Sutherland continues to contribute to the evolving landscape of pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…